GM-2505

GM-2505 is an experimental psychedelic antidepressant that works as a 5-HT2A receptor agonist. Compared to other 5-HT2A receptor agonists, it has a shorter duration of action.^[1]^[2]

References[edit]

^ Hughes, Zoe; Klein, Adam; Dvorak, Dino; Austin, Eric; Kiss, Laszlo; Marek, Gerard; Sporn, Jonathan; Kruegel, Andrew (May 2023). "22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy". Biological Psychiatry. 93 (9): S102–S103. doi:10.1016/j.biopsych.2023.02.262. S2CID 258042180.
^ Beaney, Abigail (6 December 2023). "Gilgamesh to initiate Phase IIa trial of fast-acting psychedelic drug". Clinical Trials Arena. Retrieved 7 December 2023.

[1] Hughes, Zoe; Klein, Adam; Dvorak, Dino; Austin, Eric; Kiss, Laszlo; Marek, Gerard; Sporn, Jonathan; Kruegel, Andrew (May 2023). "22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy". Biological Psychiatry. 93 (9): S102–S103. doi:10.1016/j.biopsych.2023.02.262. S2CID 258042180.

[2] Beaney, Abigail (6 December 2023). "Gilgamesh to initiate Phase IIa trial of fast-acting psychedelic drug". Clinical Trials Arena. Retrieved 7 December 2023.

[1]

[2]